Most recent by Devin McLaughlin
Strategy may enable some patients with HER2-positive breast cancer to avoid chemotherapy
CHICAGO — A chemotherapy de-escalation strategy involving dual HER2 blockade resulted in high rates of 3-year invasive DFS among patients with HER2-positive early breast cancer, according to study results presented at ASCO Annual Meeting.
FDA approves Talzenna regimen for certain men with metastatic prostate cancer
FDA approved talazoparib plus enzalutamide for treatment of homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.
Selinexor maintenance extends PFS in endometrial cancer subgroup with high unmet need
Selinexor maintenance after systemic therapy extended median PFS more than four times longer than placebo for women with advanced or recurrent TP53 wild-type endometrial cancer, according to phase 3 study results.
Gilead terminates phase 3 trial of magrolimab regimen for myelodysplastic syndrome
A phase 3 trial of magrolimab plus azacitidine for higher-risk myelodysplastic syndrome has been terminated because of futility, according to a press release.
Pembrolizumab plus chemoradiotherapy extends PFS in advanced cervical cancer
The addition of pembrolizumab to concurrent chemoradiotherapy conferred a statistically significant and clinically meaningful increase in PFS among women with newly diagnosed high-risk locally advanced cervical cancer, topline data showed.
FDA approves Talzenna regimen for certain men with metastatic prostate cancer
FDA approved talazoparib plus enzalutamide for treatment of homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.
Pembrolizumab regimen fails to hit EFS target in gastric, gastroesophageal junction cancer
The addition of pembrolizumab to perioperative chemotherapy failed to significantly extend EFS among patients with locally advanced resectable gastric and gastroesophageal junction adenocarcinoma, according to the agent’s manufacturer.
ASCO chief medical officer appeals to Congress for action on cancer-drug shortages
ASCO Chief Medical Officer Julie R. Gralow, MD, FACP, FASCO, urged members of Congress to take action on cancer drug shortages, which she described as the worst she has witnessed during her 30-year career in oncology.
Mirvetuximab soravtansine data ‘practice changing’ for subset of women with ovarian cancer
CHICAGO — Mirvetuximab soravtansine-gynx extended survival of women with platinum-resistant ovarian cancer and high folate receptor-alpha expression, according to a study that compared the agent with investigator’s choice of chemotherapy.
Sintilimab reduces recurrence risk in locoregionally advanced nasopharyngeal carcinoma
CHICAGO — When added to induction chemotherapy and concurrent chemoradiotherapy, sintilimab conferred a 41% reduction in risk for disease recurrence or death among patients with high-risk locoregionally advanced nasopharyngeal carcinoma.